IV BioHoldings launched three liquid biopsy start-ups aimed at early detection and treatment of cancer and one focusing on metabolic disease: LiquidLung, HepGene and Mammogen.
Incorporated in December 2018 and funded in March 2019 with a $1m seed round, LiquidLung focuses on
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?